Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

147.68
+1.380.94%
Post-market: 146.73-0.9500-0.64%18:40 EDT
Volume:5.19M
Turnover:766.96M
Market Cap:183.22B
PE:-56.47
High:149.30
Open:146.58
Low:146.12
Close:146.30
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.07
T/O Rate:0.42%
Dividend:3.22
Dividend Rate:2.18%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.49
PE(LYR):21.78

Loading ...

Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis

TradingKey
·
Aug 06

Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

Simply Wall St.
·
Aug 05

Movement Alert|Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat

Market Focus
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05